Fluorine-18-DCFPyL

Drug Profile

Fluorine-18-DCFPyL

Alternative Names: [18F]DCFPyL; PyL

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Progenics Pharmaceuticals
  • Class Antineoplastics; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Prostate cancer

Most Recent Events

  • 22 Dec 2016 Sir Mortimer B. Davis - Jewish General Hospital plans a phase II trial for Prostate cancer (Diagnosis) in Canada (IV) (NCT03001895)
  • 01 Nov 2016 Phase-II/III clinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT02981368)
  • 05 May 2016 Progenics plans a phase II/III trial for Prostate cancer (Diagnosis) in Australia and Canada (NCT02793284; 9195463)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top